62 related articles for article (PubMed ID: 31310954)
21. Compound Kushen injection attenuates angiotensin II‑mediated heart failure by inhibiting the PI3K/Akt pathway.
Wang W; Liu D; Yang L; Chen L; Miao M; Liu Y; Yin Y; Wei M; Liu G; An Y; Zheng M
Int J Mol Med; 2023 Mar; 51(3):. PubMed ID: 36734284
[TBL] [Abstract][Full Text] [Related]
22. Single-cell RNA-sequencing uncovers compound kushen injection synergistically improves the efficacy of chemotherapy by modulating the tumor environment of breast cancer.
Liu X; Bai M; Li H; Ye P; Duan X; Wu C; Huang Z; Lu S; Zhang J; Zhao Z; Guo F; You R; Qin W; Wang W; Han A; Shen L; Wang Y; Zhao Z; Luo H; Wu J
Front Immunol; 2022; 13():965342. PubMed ID: 36389835
[TBL] [Abstract][Full Text] [Related]
23. Downregulation of PRMT5 by AMI-1 enhances therapeutic efficacy of compound kushen injection in lung carcinoma in vitro and in vivo.
Yang R; Dong S; Zhang J; Zhu S; Miao G; Zhang B
Mol Cell Biochem; 2023 May; 478(5):1031-1044. PubMed ID: 36214894
[TBL] [Abstract][Full Text] [Related]
24. Cell cycle arrest is an important mechanism of action of compound Kushen injection in the prevention of colorectal cancer.
Sun J; Li M; Lin T; Wang D; Chen J; Zhang Y; Mu Q; Su H; Wu N; Liu A; Yu Y; Liu Y; Wang S; Yu X; Guo J; Yu W
Sci Rep; 2022 Mar; 12(1):4384. PubMed ID: 35288618
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of NCL attenuates tumor formation and growth in HeLa cells by targeting the PI3K/AKT pathway.
Ying J; Pan R; Tang Z; Zhu J; Ren P; Lou Y; Zhang E; Huang D; Hu P; Li D; Bao Q; Li P
Cancer Med; 2022 Mar; 11(6):1454-1464. PubMed ID: 35128835
[TBL] [Abstract][Full Text] [Related]
26. Qing-Kai-Ling Injection Acts Better Than Shen-Fu Injection in Enhancing the Antitumor Effect of Gefitinib in Resistant Non-Small Cell Lung Cancer Models.
Yu YY; Zhu YJ; Zou Y; Xiao ZZ; Shi S; Liu YH; Chang XS; Chen YD; Zhang HB
Evid Based Complement Alternat Med; 2021; 2021():9911935. PubMed ID: 34646330
[TBL] [Abstract][Full Text] [Related]
27. Traditional Chinese medicine reverses cancer multidrug resistance and its mechanism.
Wei J; Liu Z; He J; Liu Q; Lu Y; He S; Yuan B; Zhang J; Ding Y
Clin Transl Oncol; 2022 Mar; 24(3):471-482. PubMed ID: 34643878
[TBL] [Abstract][Full Text] [Related]
28. High Throughput Transcriptome Data Analysis and Computational Verification Reveal Immunotherapy Biomarkers of Compound Kushen Injection for Treating Triple-Negative Breast Cancer.
Liu X; Wu Y; Zhang Y; Bu D; Wu C; Lu S; Huang Z; Song Y; Zhao Y; Guo F; Ye P; Fu C; Shen L; Zhang J; Wang H; Duan X; Wu J
Front Oncol; 2021; 11():747300. PubMed ID: 34604090
[TBL] [Abstract][Full Text] [Related]
29. Lentivirus-mediated silencing of CNTN1 enhances gefitinib sensitivity by reversing epithelial-mesenchymal transition in lung adenocarcinoma A549 cells.
Hu CS; Huang JH; Yang DL; Xu C; Xu ZG; Tan HB; Chen ZZ
Oncol Lett; 2021 Jun; 21(6):433. PubMed ID: 33868471
[TBL] [Abstract][Full Text] [Related]
30. The Local Anesthetic Bupivacaine Inhibits the Progression of Non-Small Cell Lung Cancer by Inducing Autophagy Through Akt/mTOR Signaling.
Gu JH; Liu CC; Xie JL; Ma B; Cui SM; Yang GZ; He SC
Front Oncol; 2021; 11():616445. PubMed ID: 33777755
[TBL] [Abstract][Full Text] [Related]
31. Eupafolin inhibits breast cancer cell proliferation and induces apoptosis by inhibiting the PI3K/Akt/mTOR pathway.
Wei J; Zhang X; Pan H; He S; Yuan B; Liu Q; Zhang J; Ding Y
Oncol Lett; 2021 Apr; 21(4):332. PubMed ID: 33692864
[TBL] [Abstract][Full Text] [Related]
32. Targeting c-kit inhibits gefitinib resistant NSCLC cell growth and invasion through attenuations of stemness, EMT and acquired resistance.
Zhou Y; Wang L; Sun Z; Zhang J; Wang X
Am J Cancer Res; 2020; 10(12):4251-4265. PubMed ID: 33414998
[TBL] [Abstract][Full Text] [Related]
33. Long non-coding RNA TRPM2-AS sponges microRNA-138-5p to activate epidermal growth factor receptor and PI3K/AKT signaling in non-small cell lung cancer.
Cui D; Feng Y; Shi K; Zhang H; Qian R
Ann Transl Med; 2020 Oct; 8(20):1313. PubMed ID: 33209893
[TBL] [Abstract][Full Text] [Related]
34. Integrated bioinformatics analysis to decipher molecular mechanism of compound Kushen injection for esophageal cancer by combining WGCNA with network pharmacology.
Zhou W; Wu J; Zhang J; Liu X; Guo S; Jia S; Zhang X; Zhu Y; Wang M
Sci Rep; 2020 Jul; 10(1):12745. PubMed ID: 32728182
[TBL] [Abstract][Full Text] [Related]
35. Anti-Tumor Activities of Bioactive Phytochemicals in
Cao X; He Q
Cancer Manag Res; 2020; 12():1457-1467. PubMed ID: 32161498
[TBL] [Abstract][Full Text] [Related]
36. Study on the mechanisms of compound Kushen injection for the treatment of gastric cancer based on network pharmacology.
Zhou W; Wu J; Zhu Y; Meng Z; Liu X; Liu S; Ni M; Jia S; Zhang J; Guo S
BMC Complement Med Ther; 2020 Jan; 20(1):6. PubMed ID: 32020871
[TBL] [Abstract][Full Text] [Related]
37. An effective drug sensitizing agent increases gefitinib treatment by down regulating PI3K/Akt/mTOR pathway and up regulating autophagy in non-small cell lung cancer.
Zhang J; Qu Z; Yao H; Sun L; Harata-Lee Y; Cui J; Aung TN; Liu X; You R; Wang W; Hai L; Adelson DL; Lin L
Biomed Pharmacother; 2019 Oct; 118():109169. PubMed ID: 31310954
[TBL] [Abstract][Full Text] [Related]
38. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
Zheng R; Jiang H; Li J; Liu X; Xu H
Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
[TBL] [Abstract][Full Text] [Related]
39. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
40. Linc01014 regulates gefitinib resistance in oesophagus cancer via EGFR-PI3K-AKT-mTOR signalling pathway.
Fu X; Cui G; Liu S; Zhao S
J Cell Mol Med; 2020 Jan; 24(2):1670-1675. PubMed ID: 31785047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
